Literature DB >> 6810286

[Synergistic activity between ticarcillin, azlocillin, cefsulodin, ceftazidime and tobramycin or amikacin against Pseudomonas aeruginosa (author's transl)].

J C Petit, G Richard, B Burghoffer, G L Daguet.   

Abstract

Activity of azlocillin, cefsulodin, ceftazidime, ticarcillin in combination with amikacin or tobramycin was investigated against 17 Pseudomonas aeruginosa isolates. Synergistic activity was evaluated by the microtiter checkerboard technique. The bactericidal effect of the antibiotic combination was determined by subculturing onto agar and into broth. Synergistic activities of cefsulodin and ticarcillin combined with amikacin or tobramycin were similar in the inhibitory as well as in the bactericidal tests. Synergistic effects of the combination of ceftazidime and amikacin or tobramycin were moderate or indifferent in the inhibitory and bactericidal tests. The combination of azlocillin and amikacin or tobramycin produced synergistic effects greater in bactericidal tests than in inhibitory tests. The bactericidal synergistic activities of the combinations of azlocillin, cefsulodin, ticarcillin were similar. There was no difference between amikacin and tobramycin combined with a beta-lactamine. Antagonism was not observed. A synergistic effect of the combinations was observed against 4 isolates resistant to tobramycin and/or ticarcillin. However the result of the interaction seemed to depend upon the level of resistance to the antibiotic : if the MIC or the MBC of either antibiotic in the test combination was very high, synergy could not be achieved.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6810286

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  2 in total

1.  [Comparative in vitro study of the antimicrobial activity of ceftazidime against clinical isolates].

Authors:  W Klietmann; J Focht; K Nösner
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 2.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.